Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy

被引:9
|
作者
Harland, Aubrie A. [1 ]
Pogozheva, Irina D. [1 ]
Griggs, Nicholas W. [2 ]
Trask, Tyler J. [2 ]
Traynor, John R. [2 ]
Mosberg, Henry I. [1 ,3 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Sch, Dept Pharmacol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Interdept Program Med Chem, Ann Arbor, MI 48109 USA
来源
ACS CHEMICAL NEUROSCIENCE | 2017年 / 8卷 / 11期
关键词
Mixed-efficacy opioid ligands; kappa opioid receptor agonist; mu opioid receptor agonist; peptidomimetics; structure-activity relationships; BUTANESULFINYL-PROTECTED AMINES; POT ASYMMETRIC-SYNTHESIS; MORPHINE-TOLERANCE; HIGHLY POTENT; AGONIST; ANTAGONIST; LIGANDS; DEPENDENCE; COMPLEX; SUBSTITUTIONS;
D O I
10.1021/acschemneuro.7b00284
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In an effort to expand the structure-activity relationship (SAR) studies of a series of mixed-efficacy opioid ligands, peptidomimetics that incorporate methoxy and hydroxy groups around a benzyl or 2-methylindanyl pendant on a tetrahydroquinoline (THQ) core of the peptidomimetics were evaluated. Compounds containing a methoxy or hydroxy moiety in the o- or m-positions increased binding affinity to the kappa opioid receptor (KOR), whereas compounds containing methoxy or hydroxy groups in the p-position decreased KOR affinity and reduced or eliminated efficacy at the mu opioid receptor (MOR). The results from a substituted 2-methylindanyl series aligned with the findings from the substituted benzyl series. Our studies culminated in the development of 8c, a mixed-efficacy MOR agonist/KOR agonist with subnanomolar binding affinity for both MOR and KOR.
引用
收藏
页码:2549 / 2557
页数:9
相关论文
共 28 条
  • [21] Morphine withdrawal precipitated by specific mu, delta or kappa opioid receptor antagonists: a c-Fos protein study in the rat central nervous system
    Le Guen, S
    Gestreau, C
    Besson, JM
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 17 (11) : 2425 - 2437
  • [22] Non-neuronal kappa-opioid receptor activation enhances epidermal keratinocyte proliferation, and modulates mast cell functions in human skinex vivo
    Cheret, Jeremy
    Gherardini, Jennifer
    Soeberdt, Michael
    Hundt, Jennifer E.
    Abels, Christoph
    Bertolini, Marta
    Paus, Ralf
    JOURNAL OF DERMATOLOGY, 2020, 47 (08) : 917 - 921
  • [23] Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats
    Altarifi, Ahmad A.
    Yuan, Yunyun
    Zhang, Yan
    Selley, Dana E.
    Negus, S. Stevens
    PSYCHOPHARMACOLOGY, 2015, 232 (04) : 815 - 824
  • [24] BUTORPHANOLS EFFICACY AT MU-OPIOID AND KAPPA-OPIOID RECEPTORS - INFERENCES BASED ON THE SCHEDULE-CONTROLLED BEHAVIOR OF NONTOLERANT AND MORPHINE-TOLERANT RATS AND ON THE RESPONDING OF RATS UNDER A DRUG DISCRIMINATION PROCEDURE
    PICKER, MJ
    NEGUS, SS
    CRAFT, RM
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 36 (03) : 563 - 568
  • [25] In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator
    Obeng, Samuel
    Yuan, Yunyun
    Jali, Abdulmajeed
    Selley, Dana E.
    Zhang, Yan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 827 : 32 - 40
  • [26] Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment Efficacy
    Schrader, Thomas O.
    Lorrain, Kym I.
    Bagnol, Didier
    Edu, Geraldine C.
    Broadhead, Alexander
    Baccei, Christopher
    Poon, Michael M.
    Stebbins, Karin J.
    Xiong, Yifeng
    Lorenzana, Ariana O.
    Chan, Jonah R.
    Green, Ari J.
    Lorrain, Daniel S.
    Chen, Austin
    ACS CHEMICAL NEUROSCIENCE, 2024, 15 (03): : 685 - 698
  • [27] Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids
    Vidal-Torres, Alba
    Fernandez-Pastor, Begona
    Garcia, Monica
    Ayet, Eva
    Cabot, Anna
    Burgueno, Javier
    Monroy, Xavier
    Aubel, Bertrand
    Codony, Xavier
    Romero, Luz
    Pascual, Rosalia
    Serafini, Maria Teresa
    Encina, Gregorio
    Almansa, Carmen
    Zamanillo, Daniel
    Merlos, Manuel
    Vela, Jose Miguel
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (01) : 82 - 99
  • [28] Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy
    Santos, Edna J.
    Nassehi, Nima
    Bow, Eric W.
    Chambers, Dana R.
    Gutman, Eugene S.
    Jacobson, Arthur E.
    Lutz, Joshua A.
    Marsh, Samuel A.
    Rice, Kenner C.
    Sulima, Agnieszka
    Selley, Dana E.
    Negus, S. Stevens
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (04):